Experience

Represented Daiichi Sankyo in its global phase 3 collaboration & license agreement with AstraZeneca for Enhertu™ (co-dev and profit-sharing). $6B+ potential deal value.

Represented Astellas in its global preclinical collaboration with Sutro Biopharma to discover, develop, and commercialize novel immunostimulatory ADCs. $1B+ potential deal value.

Represented Prothena in its global preclinical collaboration and option agreement to discover, develop, and commercialize novel antibodies for neurodegenerative diseases. $2B+ potential deal value.

Represented Astellas Gene Therapies in its exclusive license and option agreement with 4D Molecular Therapeutics to license its R100 vector for rare monogenic ophthalmic diseases. $900M+ potential deal value.

Represented Ascendis Pharma in its formation of Visen Pharma as a JV to operate in China.

Represented Mapi Pharma in its exclusive license and supply agreement with Mylan to develop and commercialize Mapi’s GA Depot product.

Represented Coherus BioSciences in its exclusive commercial license to BioEQ’s ranibizumab biosimilar for the U.S.

Represented Corvus Pharmaceuticals in its exclusive license with Monash University to an undisclosed immuno-oncology program.

Represented Astellas in multiple asset divestments of shelved programs (preclinical and clinical).

Represented Astellas Venture Management (AVM) in a strategic investment in Mogrify (in vivo cell reprogramming) as part of a $46M Series A.

Represented AVM in a strategic investment in Shinobi Therapeutics as part of a $51M Series A.

Represented AVM in a strategic investment in Neophore (DNA mismatch repair) as part of a $40M Series B.

Represented AVM in a strategic investment in Carbon Biosciences (gene therapy) as part of a $38M Series A.

Represented AVM in a strategic investment in Catamaran Bio (synthetic innate immunology) as part of a $23M Series A.

Represented AVM in a number of strategic seed investments, as well as convertible note and SAFE bridge financings for various portfolio companies (undisclosed).

Astellas Pharma US LLC (4.5 years)

Latham & Watkins LLP (6 years)

UC Berkeley School of Law (J.D., 2014)

• Alumni of the Startup Law Initiative (clinic), the Samuelson Law Technology, & Public Policy Clinic and the Berkeley Technology Law Journal

Duke University (B.S., Neuroscience, 2010)

BIO International Convention, “Platform Licensing: Biotech and Pharma Perspectives” (Panelist, Boston, planned June 2025)

Life Sciences MoForum, “The State of the Life Sciences Investment Market” (Panelist, San Diego, September 2024)

BIO International Convention, San Diego, “Creative Structures for Keeping Innovation Alive After the Deal” (Panelist, San Diego, June 2024)

“Value Balance: IP Ownership & Structuring Considerations in Complex Collaborations and Licensing Transactions” (Astellas Internal Training, Co-Host)

“Indemnification 101” (Astellas Internal On-Demand Training, Presenter)